Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
The discovery of an echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene led to improved clinical outcomes in patients with lung cancer after the development of the first ALK-targeting agent, crizotinib. Some second-generation ALK tyrosine kinase inhib...
Main Authors: | , , |
---|---|
Format: | Online |
Language: | English |
Published: |
MDPI
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491683/ |